Odan Laboratories
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
325 Av Stillview, Pointe-Claire, Quebec,...Phone Number
(212) 253-7126Website
www.odanlab.comRevenue
$23.4 MillionIndustry
About Odan Laboratories
Verlyx, a clinical stage biopharmaceutical company based in Montreal, specializes in the development of its lead compound VLX103 and its analogs for treating gastrointestinal diseases. The safety and efficacy of these products are currently under investigation, and they have not yet received market authorization from Health Canada. Following its acquisition by Odan Laboratories Ltd., Verlyx aims to enhance and diversify its research and development activities. The intended clients are primarily within Canada, as the products are available for billing and shipping only to Canadian addresses.Explore more
Odan Laboratories Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Odan Laboratories
Compare insights from companies similar to Odan Laboratories, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$68.5M
51-200
Private
$6M
1983
Odan Laboratories Tech Stack
A closer look at the technologies used by Odan Laboratories
See more technologies
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Odan Laboratories
Sign Up For FreeTo access detailed company insights
Verlyx, a clinical stage biopharmaceutical company based in Montreal, specializes in the development of its lead compound VLX103 and its analogs for treating gastrointestinal diseases. The safety and efficacy of these products are currently under investigation, and they have not yet received market authorization from Health Canada. Following its ac... Read More
